8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Feb 4, 2026·SEC
Verastem, Inc.(VSTM)Earnings, Financials & Key Ratios
VSTM•NASDAQ
Price updated Jun 11, 2026
AboutVerastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.Show more
- Revenue$31M+209.1%
- EBITDA-$169M-47.4%
- Net Income-$209M-60.3%
- EPS (Diluted)-3.02+17.5%
- Gross Margin82.86%-17.1%
- EBITDA Margin-547.98%+52.3%
- Operating Margin-550.33%+52.1%
- Net Margin-677.59%+48.1%
- ROE-1480.15%-61.3%
- Debt/Equity1.34
- Interest Coverage-149.50-441.8%
VSTM Key Insights
Verastem, Inc. (VSTM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 25.3% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Sales declining 19.0% over 5 years
- ✗Shares diluted 94.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VSTM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VSTM Price & Volume
Verastem, Inc. (VSTM) stock price & volume — 10-year historical chart
Loading chart...
VSTM Growth Metrics
Verastem, Inc. (VSTM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-18.97%
3 Years128.36%
TTM395.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.53%
Return on Capital
10 Years-80.42%
5 Years-98.9%
3 Years-117.07%
Last Year-139.03%
VSTM Recent Earnings
Verastem, Inc. (VSTM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 3/12 qtrs (43%)
Q2 2026Latest
May 7, 2026EPS
$0.46
Est $0.46
+0.0%
Revenue
$19M
Est $21M
-12.9%
Q2 2026
Mar 4, 2026EPS
$0.39
Est $0.49
+20.4%
Revenue
$18M
Est $17M
+3.7%
Q4 2025
Nov 4, 2025EPS
$1.35
Est $0.51
-164.7%
Revenue
$11M
Est $17M
-32.0%
Q3 2025
Aug 7, 2025EPS
$0.39
Est $0.85
+54.1%
Revenue
$2M
Est $6M
-62.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.46vs $0.46+0.0% | $19Mvs $21M-12.9% |
| Q2 2026 | Mar 4, 2026 | $0.39vs $0.49+20.4% | $18Mvs $17M+3.7% |
| Q4 2025 | Nov 4, 2025 | $1.35vs $0.51-164.7% | $11Mvs $17M-32.0% |
| Q3 2025 | Aug 7, 2025 | $0.39vs $0.85+54.1% | $2Mvs $6M-62.5% |
Based on last 12 quarters of dataView full earnings history →
VSTM Peer Comparison
Verastem, Inc. (VSTM) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KPTI | 76.84M | 9.00 | -0.50 | 0.57% | -129.02% | |||
 MGNX | 254.89M | 4.01 | -3.40 | 0.78% | -44.79% | -147.8% | 1.92 | |
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 PRME | 509.34M | 2.82 | -2.09 | 55.28% | -49.18% | -188.82% | 0.96 | |
 AGEN | 141.17M | 3.39 | -997.06 | 10.37% | 52.16% | |||
 IDYA | 2.53B | 28.84 | -22.53 | 30.24% | -62.17% | -13.96% | 0.03 | |
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare VSTM vs Peers
Verastem, Inc. (VSTM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VSTM Income Statement
Verastem, Inc. (VSTM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 26.72M | 17.46M | 88.52M | 2.05M | 2.6M | 0 | 10M | 30.91M | 49.59M |
Revenue Growth % | - | - | -34.67% | 407.08% | -97.68% | 26.45% | -100% | - | 209.14% | 395.85% |
Cost of Goods Sold | 556K | 588K | 2.81M | 33.74M | 0 | 0 | 0 | 0 | 5.3M | 8.06M |
COGS % of Revenue | - | 2.2% | 16.08% | 38.12% | - | - | - | - | 17.14% | - |
Gross Profit | -556K▲ 0% | 26.13M▲ 4799.6% | 14.65M▼ 43.9% | 54.77M▲ 273.9% | 2.05M▼ 96.3% | 2.6M▲ 26.4% | 0▼ 100.0% | 10M▲ 0% | 25.62M▲ 156.2% | 41.53M▲ 0% |
Gross Margin % | - | 97.8% | 83.92% | 61.88% | 100% | 100% | - | 100% | 82.86% | 83.75% |
Gross Profit Growth % | 17.01% | 4799.64% | -43.94% | 273.89% | -96.25% | 26.45% | -100% | - | 156.16% | - |
Operating Expenses | 67.8M | 120.91M | 146.99M | 104.13M | 63.46M | 75.53M | 92.08M | 124.96M | 195.75M | 212.38M |
OpEx % of Revenue | - | 452.55% | 842.06% | 117.64% | 3091.18% | 2909.59% | - | 1249.56% | 633.19% | - |
Selling, General & Admin | 21.38M | 77.27M | 101.21M | 62.76M | 24.11M | 24.98M | 30.73M | 43.62M | 81.15M | 88.42M |
SG&A % of Revenue | - | 289.19% | 579.81% | 70.9% | 1174.62% | 962.06% | - | 436.22% | 262.49% | - |
Research & Development | 46.42M | 43.65M | 45.78M | 41.38M | 39.35M | 50.56M | 61.36M | 81.33M | 114.6M | 123.67M |
R&D % of Revenue | - | 163.37% | 262.25% | 46.74% | 1916.56% | 1947.53% | - | 813.34% | 370.7% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 290K |
Operating Income | -67.8M▲ 0% | -94.78M▼ 39.8% | -132.34M▼ 39.6% | -49.36M▲ 62.7% | -61.41M▼ 24.4% | -72.94M▼ 18.8% | -92.08M▼ 26.3% | -114.96M▼ 24.8% | -170.13M▼ 48.0% | -170.85M▲ 0% |
Operating Margin % | - | -354.75% | -758.14% | -55.76% | -2991.18% | -2809.59% | - | -1149.56% | -550.33% | -344.56% |
Operating Income Growth % | -83.24% | -39.79% | -39.63% | 62.7% | -24.41% | -18.77% | -26.25% | -24.84% | -47.99% | - |
EBITDA | -67.25M | -93.36M | -130.16M | -48.1M | -61.34M | -72.82M | -92.02M | -114.93M | -169.4M | -169.85M |
EBITDA Margin % | - | -349.44% | -745.66% | -54.35% | -2987.68% | -2805.05% | - | -1149.3% | -547.98% | -342.55% |
EBITDA Growth % | -85.09% | -38.84% | -39.41% | 63.04% | -27.51% | -18.72% | -26.37% | -24.89% | -47.39% | -29.62% |
D&A (Non-Cash Add-back) | 556K | 1.42M | 2.18M | 1.25M | 72K | 118K | 62K | 26K | 728K | 997K |
EBIT | -67.24M | -66.62M | -128.6M | -51.74M | -61.23M | -71.67M | -83.23M | -125.89M | -170.13M | -210.61M |
Net Interest Income | 2K | -3.21M | -16.23M | -15.28M | -9.79M | -922K | 2.08M | -413K | 2.93M | 3.08M |
Interest Income | 561K | 2.6M | 4.38M | 515K | 181K | 1.22M | 6.21M | 4.15M | 4.07M | 4.08M |
Interest Expense | 559K | 5.81M | 20.61M | 15.79M | 9.97M | 2.14M | 4.14M | 4.56M | 1.14M | 1.01M |
Other Income/Expense | 2K | 22.35M | -16.87M | -18.17M | -9.79M | -875K | 4.72M | -15.5M | -39.34M | -23.11M |
Pretax Income | -67.8M▲ 0% | -72.43M▼ 6.8% | -149.21M▼ 106.0% | -67.53M▲ 54.7% | -71.2M▼ 5.4% | -73.81M▼ 3.7% | -87.37M▼ 18.4% | -130.45M▼ 49.3% | -209.47M▼ 60.6% | -193.96M▲ 0% |
Pretax Margin % | - | -271.11% | -854.77% | -76.29% | -3468.1% | -2843.3% | - | -1304.52% | -677.59% | -391.16% |
Income Tax | 561K | 0 | 0 | 194K | 0 | 0 | 0 | 185K | 0 | 0 |
Effective Tax Rate % | -0.83% | 0% | 0% | -0.29% | 0% | 0% | 0% | -0.14% | 0% | 0% |
Net Income | -67.8M▲ 0% | -72.43M▼ 6.8% | -149.21M▼ 106.0% | -67.73M▲ 54.6% | -71.2M▼ 5.1% | -73.81M▼ 3.7% | -87.37M▼ 18.4% | -130.64M▼ 49.5% | -209.47M▼ 60.3% | -193.96M▲ 0% |
Net Margin % | - | -271.11% | -854.77% | -76.51% | -3468.1% | -2843.3% | - | -1306.37% | -677.59% | -391.16% |
Net Income Growth % | -86.06% | -6.83% | -105.99% | 54.61% | -5.13% | -3.67% | -18.36% | -49.53% | -60.35% | -30.28% |
Net Income (Continuing) | -67.8M | -72.43M | -149.21M | -67.73M | -71.2M | -73.81M | -87.37M | -130.64M | -209.47M | -193.96M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -21.18▲ 0% | -12.54▲ 40.8% | -27.22▼ 117.1% | -5.28▲ 80.6% | -4.92▲ 6.8% | -4.57▲ 7.1% | -3.96▲ 13.3% | -3.66▲ 7.6% | -3.02▲ 17.5% | -1.96▲ 0% |
EPS Growth % | -79.19% | 40.79% | -117.07% | 80.6% | 6.82% | 7.11% | 13.35% | 7.58% | 17.49% | 23.53% |
EPS (Basic) | -21.18 | -12.54 | -27.22 | -5.28 | -4.92 | -4.57 | -3.96 | -3.66 | -3.02 | - |
Diluted Shares Outstanding | 3.2M | 5.78M | 6.21M | 12.78M | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M | 99.15M |
Basic Shares Outstanding | 3.2M | 5.78M | 6.21M | 12.78M | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M | 98.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VSTM Balance Sheet
Verastem, Inc. (VSTM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 87.79M | 253.26M | 84.96M | 144.94M | 105.74M | 92.87M | 143.68M | 94.96M | 223.41M | 202.9M |
Cash & Short-Term Investments | 86.67M | 249.65M | 75.51M | 141.23M | 100.26M | 87.89M | 137.13M | 88.82M | 204.99M | 181.68M |
Cash Only | 82.18M | 129.87M | 43.51M | 67.78M | 21.25M | 74.93M | 77.91M | 88.82M | 204.99M | 165.55M |
Short-Term Investments | 4.5M | 119.79M | 31.99M | 73.44M | 79M | 12.96M | 59.22M | 0 | 0 | 16.13M |
Accounts Receivable | 0 | 306K | 2.52M | 239K | 516K | 31K | 0 | 200K | 8.81M | 10.36M |
Days Sales Outstanding | - | 4.18 | 52.78 | 0.99 | 91.74 | 4.36 | - | 7.3 | 104.05 | 35.98 |
Inventory | 0 | 327K | 3.1M | 0 | 0 | 0 | 0 | 0 | 1.83M | 2.29M |
Days Inventory Outstanding | - | 202.98 | 402.58 | - | - | - | - | - | 126.28 | 80.2 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 6.55M | 5.94M | 7.78M | 8.58M |
Total Non-Current Assets | 2M | 23.98M | 60.09M | 9.41M | 2.92M | 2.18M | 6.04M | 6.58M | 23.03M | 24.9M |
Property, Plant & Equipment | 861K | 1.37M | 4.02M | 3.14M | 2.51M | 1.88M | 1.21M | 1.44M | 491K | 2.79M |
Fixed Asset Turnover | - | 19.52x | 4.34x | 28.17x | 0.82x | 1.38x | - | 6.96x | 62.96x | 39.53x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 21.58M | 20.01M | 0 | 0 | 0 | 0 | 0 | 16.43M | 16.15M |
Long-Term Investments | 0 | 0 | 0 | 6M | 0 | 241K | 0 | 0 | 0 | 241K |
Other Non-Current Assets | 1.14M | 1.03M | 36.05M | 274K | 410K | 58K | 4.83M | 5.14M | 6.11M | 5.72M |
Total Assets | 89.79M▲ 0% | 277.24M▲ 208.8% | 145.05M▼ 47.7% | 154.35M▲ 6.4% | 108.66M▼ 29.6% | 95.05M▼ 12.5% | 149.72M▲ 57.5% | 101.54M▼ 32.2% | 246.44M▲ 142.7% | 227.81M▲ 0% |
Asset Turnover | - | 0.10x | 0.12x | 0.57x | 0.02x | 0.03x | - | 0.10x | 0.13x | 0.23x |
Asset Growth % | 7.37% | 208.76% | -47.68% | 6.41% | -29.6% | -12.53% | 57.52% | -32.18% | 142.71% | 341.22% |
Total Current Liabilities | 17.13M | 37.08M | 29.89M | 17.09M | 18.59M | 21.66M | 26.38M | 30.97M | 72.27M | 66.84M |
Accounts Payable | 9.19M | 10.25M | 9.65M | 1.88M | 2.3M | 4.9M | 7.18M | 4.03M | 12.45M | 9.6M |
Days Payables Outstanding | 6.03K | 6.36K | 1.26K | 20.28 | - | - | - | - | 857.59 | 452.8 |
Short-Term Debt | 0 | 5.72M | 0 | 0 | 0 | 275K | 0 | 0 | 535K | 6.29M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 710K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.7M | 11.88M | 7.85M | 5.93M | 3.89M | 11.14M | 5.12M | 6.25M | 59.28M | 43.04M |
Current Ratio | 5.13x | 6.83x | 2.84x | 8.48x | 5.69x | 4.29x | 5.45x | 3.07x | 3.09x | 3.04x |
Quick Ratio | 5.13x | 6.82x | 2.74x | 8.48x | 5.69x | 4.29x | 5.45x | 3.07x | 3.07x | 3.00x |
Cash Conversion Cycle | - | -6.16K | -800.1 | - | - | - | - | - | -627.25 | -336.62 |
Total Non-Current Liabilities | 14.98M | 115.86M | 107.98M | 21.98M | 2.51M | 26M | 65.96M | 99.46M | 116.98M | 79.19M |
Long-Term Debt | 14.83M | 114.74M | 103.62M | 19.05M | 249K | 24.53M | 40.09M | 40.72M | 76.33M | 76.87M |
Capital Lease Obligations | 0 | 0 | 3.49M | 2.93M | 2.26M | 1.47M | 530K | 535K | 0 | 2.32M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 151K | 1.12M | 870K | 0 | 0 | 0 | 25.35M | 58.2M | 40.65M | 0 |
Total Liabilities | 32.11M | 152.94M | 137.87M | 39.08M | 21.1M | 47.66M | 92.34M | 130.43M | 189.25M | 146.03M |
Total Debt | 14.83M | 120.45M | 107.53M | 22.54M | 3.18M | 27.07M | 41.56M | 42.25M | 76.86M | 85.47M |
Net Debt | -67.35M | -9.41M | 64.02M | -45.24M | -18.07M | -47.87M | -36.35M | -46.56M | -128.13M | -80.08M |
Debt / Equity | 0.26x | 0.97x | 14.99x | 0.20x | 0.04x | 0.57x | 0.72x | - | 1.34x | 1.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.50x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.47x |
Interest Coverage | -120.29x | -11.47x | -6.24x | -3.28x | -6.14x | -33.54x | -20.11x | -27.60x | -149.50x | -208.73x |
Total Equity | 57.68M▲ 0% | 124.3M▲ 115.5% | 7.17M▼ 94.2% | 115.27M▲ 1506.8% | 87.56M▼ 24.0% | 47.39M▼ 45.9% | 57.37M▲ 21.1% | -28.89M▼ 150.4% | 57.2M▲ 298.0% | 81.78M▲ 0% |
Equity Growth % | -20.21% | 115.48% | -94.23% | 1506.83% | -24.04% | -45.88% | 21.07% | -150.36% | 297.96% | 492.03% |
Book Value per Share | 18.02 | 21.52 | 1.15 | 9.02 | 6.02 | 2.94 | 2.60 | -0.81 | 0.83 | 0.82 |
Total Shareholders' Equity | 57.68M | 124.3M | 7.17M | 115.27M | 87.56M | 47.39M | 57.37M | -28.89M | 57.2M | 81.78M |
Common Stock | 5K | 7K | 8K | 17K | 19K | 20K | 3K | 4K | 8K | 9K |
Retained Earnings | -303.14M | -375.58M | -524.78M | -592.51M | -663.71M | -737.52M | -824.89M | -955.53M | -1.16B | -1.2B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2K | 127K | 14K | 53K | 34K | 0 | 13K | 0 | 5.23M | 8.62M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VSTM Cash Flow Statement
Verastem, Inc. (VSTM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -57.31M | -74.52M | -138.52M | -33.51M | -53.5M | -63.67M | -86.46M | -104.77M | -137.51M | -150.95M |
Operating CF Margin % | - | -278.89% | -793.53% | -37.85% | -2606.04% | -2452.73% | - | -1047.71% | -444.81% | - |
Operating CF Growth % | -94.38% | -30.02% | -85.89% | 75.81% | -59.68% | -19.01% | -35.79% | -21.18% | -31.25% | -124.77% |
Net Income | -67.8M | -72.43M | -149.21M | -67.73M | -71.2M | -73.81M | -87.37M | -130.64M | -209.47M | -193.96M |
Depreciation & Amortization | 556K | 1.42M | 2.18M | 1.25M | 72K | -36K | 62K | 26K | 728K | 997K |
Stock-Based Compensation | 5.03M | 6.67M | 8.54M | 8.12M | 7.71M | 6.05M | 5.86M | 7.34M | 9.4M | 9.66M |
Deferred Taxes | 0 | -25.64M | 641K | 2.89M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 223K | 1.81M | 7.13M | 10.32M | 9.33M | 228K | -4.06M | 14.78M | 35.83M | 19.18M |
Working Capital Changes | 4.68M | 13.65M | -7.8M | 11.63M | 584K | 3.9M | -957K | 3.72M | 26M | 13.17M |
Change in Receivables | 0 | -306K | -2.22M | 2.29M | -277K | 485K | 31K | -200K | -8.81M | -10.16M |
Change in Inventory | 0 | -327K | -2.77M | 3.1M | 0 | 0 | 0 | 0 | -1.83M | -1.12M |
Change in Payables | 5.05M | 1.05M | -598K | -7.98M | 623K | 2.6M | 2.28M | -3.16M | 8.42M | 2.4M |
Cash from Investing | 43.95M | -138.38M | 89.61M | -47.36M | 87K | 66.19M | -44.45M | 59.97M | -9.62M | -25.64M |
Capital Expenditures | 0 | -23.51M | -7K | -33K | -196K | 0 | 0 | -28K | -9.62M | -9.62M |
CapEx % of Revenue | - | 87.98% | 0.04% | 0.04% | 9.55% | - | - | 0.28% | 31.13% | 19.41% |
Acquisitions | 0 | 22M | 7.13M | 10.32M | 9.33M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -21.92M | -7.13M | -10.32M | -9.33M | 0 | 0 | 5K | -29K | 119K |
Cash from Financing | 63.18M | 261.16M | -2.44M | 69.63M | 6.88M | 51.78M | 134.19M | 54.78M | 263.31M | 224.57M |
Debt Issued (Net) | 14.81M | 155.2M | -2.5M | -37.37M | 0 | 24.15M | 14.62M | -150K | 32.42M | -1.19M |
Equity Issued (Net) | 48.07M | 105.16M | 0 | 106.06M | 6.72M | 27.35M | 119.52M | 14.22M | 230.88M | 216.27M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 304K | 809K | 63K | 937K | 162K | 282K | 57K | 40.71M | 0 | 9.48M |
Net Change in Cash | 49.83M▲ 0% | 48.27M▼ 3.1% | -51.35M▼ 206.4% | -11.24M▲ 78.1% | -46.53M▼ 314.0% | 54.3M▲ 216.7% | 3.29M▼ 93.9% | 9.98M▲ 203.7% | 116.17M▲ 1063.7% | 47.98M▲ 0% |
Free Cash Flow | -57.31M▲ 0% | -98.02M▼ 71.0% | -138.53M▼ 41.3% | -33.54M▲ 75.8% | -53.7M▼ 60.1% | -63.67M▼ 18.6% | -86.46M▼ 35.8% | -104.8M▼ 21.2% | -137.51M▼ 31.2% | -150.95M▲ 0% |
FCF Margin % | - | -366.88% | -793.57% | -37.89% | -2615.59% | -2452.73% | - | -1047.99% | -444.81% | -304.42% |
FCF Growth % | -94.12% | -71.04% | -41.32% | 75.79% | -60.11% | -18.58% | -35.79% | -21.21% | -31.21% | -31.09% |
FCF per Share | -17.90 | -16.97 | -22.29 | -2.62 | -3.69 | -3.95 | -3.92 | -2.93 | -1.98 | -1.52 |
FCF Conversion (FCF/Net Income) | 0.85x | 1.03x | 0.93x | 0.49x | 0.75x | 0.86x | 0.99x | 0.80x | 0.66x | 0.78x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 3.36M | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VSTM Key Ratios
Verastem, Inc. (VSTM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -104.33% | -79.61% | -226.98% | -110.62% | -70.21% | -109.39% | -166.79% | -917.36% | -1480.15% | -486.41% |
| Return on Invested Capital (ROIC) | -335.84% | -135.12% | -106.68% | -52.43% | -66.02% | -158.54% | -672.31% | - | - | 308.34% |
| Gross Margin | - | 97.8% | 83.92% | 61.88% | 100% | 100% | - | 100% | 82.86% | 83.75% |
| Net Margin | - | -271.11% | -854.77% | -76.51% | -3468.1% | -2843.3% | - | -1306.37% | -677.59% | -391.16% |
| Debt / Equity | 0.26x | 0.97x | 14.99x | 0.20x | 0.04x | 0.57x | 0.72x | - | 1.34x | 1.05x |
| Interest Coverage | -120.29x | -11.47x | -6.24x | -3.28x | -6.14x | -33.54x | -20.11x | -27.60x | -149.50x | -208.73x |
| FCF Conversion | 0.85x | 1.03x | 0.93x | 0.49x | 0.75x | 0.86x | 0.99x | 0.80x | 0.66x | 0.78x |
| Revenue Growth | - | - | -34.67% | 407.08% | -97.68% | 26.45% | -100% | - | 209.14% | 395.85% |
Related:VSTM Dividend History·VSTM Revenue History·VSTM Price History·VSTM P/E History·VSTM Financial Ratios·VSTM Institutional Holders
VSTM SEC Filings & Documents
Verastem, Inc. (VSTM) SEC filings — annual & quarterly reports (10-K, 10-Q)
VSTM Frequently Asked Questions
Verastem, Inc. (VSTM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Verastem, Inc. (VSTM) reported $49.6M in revenue for fiscal year 2025.
Verastem, Inc. (VSTM) grew revenue by 209.1% over the past year. This is strong growth.
Verastem, Inc. (VSTM) reported a net loss of $194.0M for fiscal year 2025.
Dividend & Returns
Verastem, Inc. (VSTM) has a return on equity (ROE) of -1480.2%. Negative ROE indicates the company is unprofitable.
Verastem, Inc. (VSTM) had negative free cash flow of $150.9M in fiscal year 2025, likely due to heavy capital investments.